These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

879 related items for PubMed ID: 12639642

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.
    Sawczuk IS, Pickens CL, Vasa UR, Ralph DA, Norris KA, Miller MC, Ng AY, Grossman HB, Veltri RW.
    Urol Oncol; 2002; 7(5):185-90. PubMed ID: 12644214
    [Abstract] [Full Text] [Related]

  • 3. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG, Hellstern A, Hautmann SH, Noldus I, Huland H.
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.
    Arch Esp Urol; 2002 Apr; 55(1):41-9. PubMed ID: 11957750
    [Abstract] [Full Text] [Related]

  • 6. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP, FinnBladder Group.
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S, Biri H, Sinik Z, Küpeli B, Alkibay T, Bozkirli I.
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [Abstract] [Full Text] [Related]

  • 8. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells.
    Bonner RB, Hemstreet GP, Fradet Y, Rao JY, Min KW, Hurst RE.
    Cancer; 1993 Oct 15; 72(8):2461-9. PubMed ID: 8402463
    [Abstract] [Full Text] [Related]

  • 9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug 15; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
    Lee KH.
    Yonsei Med J; 2001 Feb 15; 42(1):14-8. PubMed ID: 11293494
    [Abstract] [Full Text] [Related]

  • 12. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
    Giannopoulos A, Manousakas T, Mitropoulos D, Botsoli-Stergiou E, Constantinides C, Giannopoulou M, Choremi-Papadopoulou H.
    Urology; 2000 Jun 15; 55(6):871-5. PubMed ID: 10840098
    [Abstract] [Full Text] [Related]

  • 13. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P, Neulander E, Zirkin H, Yusim I, Douvdevani A, Mermershtain W, Kaneti J, Manor E.
    Urology; 2004 Feb 15; 63(2):398-401. PubMed ID: 14972510
    [Abstract] [Full Text] [Related]

  • 14. BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder.
    Mattioli S, Seregni E, Caperna L, Botti C, Savelli G, Bombardieri E.
    Int J Biol Markers; 2000 Feb 15; 15(3):219-25. PubMed ID: 11012097
    [Abstract] [Full Text] [Related]

  • 15. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test.
    Raitanen MP, Hellström P, Marttila T, Korhonen H, Talja M, Ervasti J, Tammela TL, Finnbladder Group.
    Eur Urol; 2001 Oct 15; 40(4):422-6. PubMed ID: 11713397
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E.
    BJU Int; 2001 Nov 15; 88(7):692-701. PubMed ID: 11890239
    [Abstract] [Full Text] [Related]

  • 18. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
    Babjuk M, Kostírová M, Mudra K, Pecher S, Smolová H, Pecen L, Ibrahim Z, Dvorácek J, Jarolím L, Novák J, Zima T.
    Eur Urol; 2002 Jan 15; 41(1):34-9. PubMed ID: 11999463
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.